Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Med LifeLTS:0RO5 +2.15%62 Debt-to-Equity is 4.08 as of Mar. 2026, which is 36% above its 10-year median of 2.99. GuruFocus rates LTS:0RO5 with a GF Score™ of 62/100 and a GF Value™ of lei1.51 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 556 Healthcare Providers & Services companies, Med Life ranks worse than 96.04% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Med Life's Debt-to-Equity or its related term are showing as below:
LTS:0RO5'
s Debt-to-Equity Range Over the Past 10 Years
Min: 1.94 Med: 2.99 Max: 4.5
Current: 4.08
During the past 11 years, the highest Debt-to-Equity Ratio of Med Life was 4.50. The lowest was 1.94. And the median was 2.99.
LTS:0RO5's Debt-to-Equity is ranked worse than 96.04% of 556
companies
in the Healthcare Providers & Services industry
Industry Median: 0.42
vs LTS:0RO5: 4.08
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Med Life Debt-to-Equity Related Terms
Med Life Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Med Life's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0RO5 vs HCA, THC, DVA: Debt-to-Equity Comparison
For the Medical Care Facilities subindustry, Med Life's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Med Life Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Med Life's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Med Life's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Med Life (LTS:0RO5) has a Debt-to-Equity of 4.08 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Med Life and its competitors. This is 36% above median its historical median of 2.99. Over the past decade, Med Life's Debt-to-Equity has ranged from 1.94 to 4.50. According to the industry distribution chart, Med Life ranks #534 out of 556 companies in the Healthcare Providers & Services industry, placing it in the top 96%.
Is Med Life's Debt-to-Equity too high?
Med Life's current Debt-to-Equity of 4.08 is 36% above median its 10-year median of 2.99. Over the past 10 years, this metric has ranged from a low of 1.94 to a high of 4.50. The Healthcare Providers & Services industry median Debt-to-Equity is 0.42. Med Life's value of 4.08 is 871.4% above this industry median. Based on the distribution chart, Med Life ranks #534 out of 556 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Med Life has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Med Life's Debt-to-Equity compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Med Life ranks #534 out of 556 companies for Debt-to-Equity. This places Med Life in the lower half of its industry. The industry median Debt-to-Equity is 0.42. Med Life's value of 4.08 is 871.4% above this benchmark. Historically, Med Life's own Debt-to-Equity has ranged from 1.94 to 4.50 over the past decade. While the company's 10-year median is 2.99 vs. the industry median of 0.42, Med Life has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 556 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Med Life's current Debt-to-Equity of 4.08 is 871.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Med Life and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Med Life's current Debt-to-Equity is 4.08, which is 36% above median its own 10-year median of 2.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Med Life stock overvalued right now?
Based on GuruFocus' analysis, Med Life (LTS:0RO5) is currently considered Significantly Overvalued. The stock's GF Value™ is lei1.51, compared to a current price of lei11.62 — trading 669.5% above its estimated fair value. The current Debt-to-Equity is 4.08, which is 36% above median its 10-year median of 2.99 and 871.4% above the Healthcare Providers & Services industry median of 0.42. Med Life's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Med Life (LTS:0RO5), the current Debt-to-Equity is 4.08 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Med Life (LTS:0RO5) Overvalued in 2026?
Based on GuruFocus' analysis, Med Life stock appears to be overvalued.
The current stock price of lei11.62 is trading 669.5% above its estimated GF Value™ of lei1.51.
GuruFocus considers Med Life to be Significantly Overvalued.
Key valuation signals for LTS:0RO5:
Debt-to-Equity: 4.08 (36% above median its 10-year median of 2.99)
GF Value™: lei1.51 vs. price of lei11.62 (669.5% above fair value)
Industry Position: 871.4% above the Healthcare Providers & Services median (#534 of 556)
No single metric tells the full story. See the LTS:0RO5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Med Life SA is a healthcare provider in Romania. The Company's activity resides in the performance of healthcare services activities through medical centres with national coverage. It is engaged in the provision of rendering of medical services, rental of medical facilities and acquisition of materials and commodities. The company provides medical service through Hyper clinics in Arad, Bucharest, Braila, Brasov, Cluj, Constanta, Craiova, Galati, Iasi, Oradea, Ploiesti, Sibiu and Timisoara; Clinics, hospitals located in Bucharest, Arad, Sibiu, Brasov, Cluj and Ploiesti, Laboratories, Pharmacies and Dental Clinics.
62GF Score
Get the complete analysis for LTS:0RO5
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0RO5 has been successfully added to your 
